Thought Leadership
Email Page
FDA Doubles Down in Its Updated Biologics Naming Guidance
March 19, 2019
Chad Landmon
The Center for Biosimilars

The Center for Biosimilars published, "FDA Doubles Down in Its Updated Biologics Naming Guidance," an article co-authored by Axinn partner Chad Landmon.

Click here to access the article.